The University of Cincinnati Cancer Center has opened the Blood Cancer Healing Center, a facility that aims to advance research, treatment, and wellness for blood cancer patients.Â
Joshua Cohn, associate professor in the Department of Urology at Fox Chase Cancer Center and a member of the Fox Chase – Temple Urologic Institute, was named a consultant at Shriners Children’s Philadelphia.Â
The Federal Trade Commission has launched an investigation into the role of hospital group purchasing organizations and dominant wholesalers in causing decades-long shortages of hundreds of lifesaving drugs.Â
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.Â
Researchers at the Spanish National Cancer Research Center and the 12 de Octubre University Hospital in Madrid have developed a new immunotherapy to treat multiple myeloma that shows, in the laboratory, to be more effective than the immunotherapy currently used as preferred treatment.
Patient-Reported Outcomes of participants in the phase II/III QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer were published by the peer-reviewed journal Urology Practice.Â
A diet that limits meat and dairy but is rich in fruits, vegetables, grains, and nuts is linked to less erectile dysfunction, urinary incontinence, and other common side effects seen in prostate cancer patients, a new study shows.
University of Florida College of Pharmacy researchers have pinpointed the genetic blueprints behind dolastatin 10, a marine natural product that has led to six FDA-approved cancer drugs since 2011.Â
Protecting free preventive cancer screenings and reducing the burden of medical debt are the top issues of concern for cancer patients and survivors today, according to a new survey by the American Cancer Society Cancer Action Network (ACS CAN) that asked participants to select their leading policy priorities for the year.
FDA has approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
